Corcept Therapeutics Incorporated (CORT) got hammered in Wednesday's premarket session, with shares cratering more than 41% after the company disclosed that the FDA had rejected its drug application for relacorilant.

The setback is particularly frustrating because, technically, Corcept's clinical trials worked. The FDA issued what's called a Complete Response Letter for the company's New Drug Application seeking approval to treat hypertension secondary to hypercortisolism, which is medical speak for high blood pressure caused by too much cortisol floating around in your system.

When Success Isn't Enough

Here's where things get tricky. The FDA actually acknowledged that Corcept's pivotal GRACE trial met its primary endpoint, and that data from the company's GRADIENT trial provided confirmatory evidence. Both trials apparently showed what they were supposed to show. But the agency concluded it couldn't arrive at a favorable benefit-risk assessment without additional evidence of effectiveness.

Translation: The FDA wants more proof before signing off, even though the existing studies technically succeeded. It's the regulatory equivalent of getting an A on the test but being told you still need to retake the class.

Understanding the Medical Context

Corcept focuses on developing medications that modulate the effects of cortisol, the stress hormone. The company targets severe endocrinologic, oncologic, metabolic, and neurologic disorders where cortisol plays a damaging role.

Hypertension is extremely common in patients with Cushing's syndrome, which results from hypercortisolism (too much cortisol). The excess cortisol mimics mineralocorticoids, increases vascular resistance, and remodels blood vessels, all of which drive blood pressure higher. It's a serious complication that needs treatment options.

The Clinical Evidence

In May 2024, Corcept announced that its GRACE Phase 3 trial of relacorilant in patients with hypercortisolism met its primary endpoint. Then in October 2024, the company reported that the 22-week Phase 3 GRADIENT study provided further support, demonstrating relacorilant's efficacy and safety profile.

On paper, everything looked good. Both studies delivered positive results. That's what makes this rejection particularly surprising.

Company Response

CEO Joseph Belanoff didn't hide his disappointment. "We are surprised and disappointed by this outcome," he said in a statement. "We will meet with the FDA as soon as possible to discuss the best path forward."

That meeting will be critical. The company needs to understand exactly what additional evidence the FDA wants and whether generating that data means running entirely new trials or if existing information can be repackaged or supplemented somehow.

Market Reaction

Investors reacted swiftly and brutally. Corcept Therapeutics shares traded down 41.25% at $41.24 during Wednesday's premarket session, hitting a new 52-week low. That's the kind of drop that happens when a key regulatory milestone suddenly looks much further away than expected.

For a commercial-stage biotech company, regulatory approval delays can be devastating, pushing out potential revenue and raising questions about how much more cash will need to be spent to satisfy regulators.